Researchers recently found that specific breast cancer tumors are more receptive to chemotherapy, which means those patients may have better clinical outcomes.
The study, published in the journal Clinical Cancer Research, used a new model to examine a person’s entire genetic makeup. It found that patients with advanced breast cancer caused by hereditary BRCA1 or BRCA2 mutations responded better to platinum-based chemotherapy.
The study focused on BRCA1 or BRCA2 mutations as they’re more likely to lack something called homologous recombination - the mechanism by which normal cells repair damaged DNA). As it turns out, this deficiency may make platinum-based chemotherapy more effective in treating breast cancer caused by BRCA1 or BRCA2 mutations.
These findings can help doctors come up with more effective treatment plans for their patients.
Source: Clinical Cancer Research, http://clincancerres.aacrjournals.org/content/23/24/7521